drugset / Trial / NCT02378688

Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's Disease

NCT02378688

Phase 2 Completed 78 enrolled Tanabe Pharma Corporation
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objectives of the study are: * To evaluate the safety and tolerability of MT-1303 in subjects with moderate to severe active Crohn's Disease(CD) * To evaluate the clinical efficacy of MT-1303 in subjects with moderate to severe active CD.

Timeline

Start
2015-03
Primary completion
2016-10
Completion
2016-10

Drugs

EvaluationDrugModalityDoseRoute
Subject amiselimod Small molecule

Indications